Hepatitis C Virus Regulates Transforming Growth Factor β1 Production Through the Generation of Reactive Oxygen Species in a Nuclear Factor κB–Dependent Manner

WENYU LIN, WEI-LUN TSAI, RUN-XUAN SHAO, GUOYANG WU, LEE F. PENG, LYDIA L. BARLOW, WOO JIN CHUNG, LEILJANG ZHANG, HONG ZHAO, JAE–YOUNG JANG, and RAYMOND T. CHUNG

Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

BACKGROUND & AIMS: The generation of oxidative stress and transforming growth factor β1 (TGF-β1) production play important roles in liver fibrogenesis. We have previously shown that hepatitis C virus (HCV) increases hepatocyte TGF-β1 expression. However, the mechanisms by which this induction occurs have not been well studied. We explored the possibility that HCV infection regulates TGF-β1 expression through the generation of reactive oxygen species (ROS), which act through p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and nuclear factor κB (NFκB) signaling pathways to induce TGF-β1 expression.

METHODS: We used small molecule inhibitors and short interfering RNAs to knock down these pathways to study the mechanism by which HCV regulates TGF-β1 production in the infectious JFH1 model. RESULTS: We demonstrated that HCV induces ROS and TGF-β1 expression. We further found that JFH1 induces the phosphorylation of p38MAPK, JNK, ERK, and NFκB. We also found that HCV-mediated TGF-β1 enhancement occurs through a ROS-induced and p38 MAPK, JNK, ERK1/2, NFκB-dependent pathway. CONCLUSIONS: These findings provide further evidence to support the hypothesis that HCV enhances hepatic fibrosis progression through the generation of ROS and induction of TGF-β1. Strategies to limit the viral induction of oxidative stress appear to be warranted to inhibit fibrogenesis.

Keywords: Hepatitis C Virus; Reactive Oxygen Species; Nuclear Factor κB; Transforming Growth Factor β1.

Hepatitis C virus (HCV) infects approximately 170 million people and is a leading cause of chronic liver disease worldwide. It is a major cause of cirrhosis, a significant cause of hepatocellular carcinoma and is the leading reason for liver transplantation worldwide. Transforming growth factor beta 1 (TGF-β1) is a regulatory cytokine with multifunctional effects on cell biological processes, including liver fibrogenesis. TGF-β1 is the most potent profibrogenic cytokine, accelerating liver fibrosis by triggering the proliferation and transformation of hepatic stellate cells (HSCs) in HCV-infected persons.

It has been reported that HCV infection is associated with a significant increase in TGF-β1 expression in both serum and liver. Adenovirus-encoded HCV core and NS3-NS5 protein expression has been shown to increase the secretion of TGF-β1 production. HCV infection has also been shown to increase hepatocyte TGF-β1 expression in cell culture models, including HCV replicon cells and JFH1 cells. However, the mechanisms by which HCV increases TGF-β1 expression have not been well studied. HCV core and HCV subgenomic replicons have each been shown to increase reactive oxygen species (ROS) production in HCV expression and replicon models. ROS may in turn induce HSC proliferation and TGF-β1 expression. ROS have also been shown to mediate TGF-β1–induced cellular responses, thereby likely playing an important role in the development of liver fibrosis associated with HCV infection. HCV core, E2, and HCV subgenomic replicons, have been shown to increase phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK), extracellular signal-regulated kinase (ERK), and activates nuclear factor κB (NFκB). However, most of this understanding was acquired with the use of the HCV replicon system or HCV protein expression model. It is still unclear how HCV infection effects ROS production and NFκB activation in cells that produce infectious HCV particles. Moreover, the mechanism by which HCV infection affects ROS production and subsequently TGF-β1 expression is still not charac-

Abbreviations used in this paper: AQ, 6-amino-4-(4-phenoxyphenyl-ethylamino) quinazoline; DMSO, dimethyl sulfoxide; DPI, diphenyldiamine; ECL, electrochemiluminescence; ERK, extracellular signal-regulated kinase; FBS, fetal bovine serum; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HCV, hepatitis C virus; HSC, hepatic stellate cell; JNK, c-Jun N-terminal kinase; LY, LY 294002; Neg, negative; NFκB, nuclear factor κB; p38 MAPK, p38 mitogen-activated protein kinase; PCR, polymerase chain reaction; PI3K, phosphoinositol-3 kinase; ROS, reactive oxygen species; SB, SB 203580; siRNA, short interfering RNA; SP, SP600125; TGF-β1, transforming growth factor beta 1.

© 2010 by the AGA Institute
0016-5085/$36.00
doi:10.1053/j.gastro.2010.03.008
terized. We hypothesized that HCV increases TGF-β1 expression through induction of ROS and activation of the p38 MAPK, c-Jun N-terminal kinase (JNK), ERK, and NFκB pathway. We tested this hypothesis with the use of the infectious JFH1 culture model.16

Materials and Methods

Cell Cultures

Huh7.5.1 cells (human hepatocellular carcinoma)17 and HCV JFH1-infected Huh7.5.1 cells16 were grown in Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine serum (FBS) medium. The JFH1-infected cells used in this study were analyzed between day 6 and 20 after infection.

ROS Measurements and Cell Viability Assay

ROS levels were measured as previously described.7,8,18 Briefly, Huh7.5.1 cells or JFH1 cells were seeded in 100 μL of 10% FBS Dulbecco’s Modified Eagle’s Medium in 96-well clear-bottom white assay plate (Corning Incorporated, Corning, NY) (10,000 cell/well) overnight (14 hours). The cells were washed with phosphate-buffered saline (PBS) and then incubated with 10 μmol/L carboxy derivative of fluorescein (Invitrogen, Carlsbad, CA) in warm PBS for 1 hour according to the manufacturer’s protocol. The treated cells were washed with PBS and then resuspended in 10% FBS. ROSs were assessed by measured fluorescence with a BioTek Synergy 2 Microplate Reader (Winooski, VT) at an excitation of 485 nm and an emission of 528 nm. Cell viability was monitored with the use of Cell Titer-Glo Luminescent Cell Viability Assay (Promega, Madison, WI). ROS level was normalized by cell viability to calculate the ROS/cell viability arbitrary unit. ROS green fluorescent images were visualized with the use of an Olympus fluorescent microscope (Olympus America Inc, Center Valley, PA; excitation, 488 nm; emission, 505–530 nm), and the images were taken with Intelligent Imaging Innovation Slide Book (Intelligent Imaging Innovations, Inc, Philadelphia, PA) software.

Immunofluorescence Analysis

To monitor the cell infectivity in the JFH1-infected cell population, we performed HCV core immunofluorescence staining in uninfected and JFH1-infected Huh7.5.1 cells (day 6 infection). Huh7.5.1 or JFH1 cells were fixed with 4% paraformaldehyde, permeabilized with 0.5% TritonX-100, and blocked with 3% bovine serum albumin in PBS. The primary antibody was mouse anti-HCV core (ViroGen Co, Watertown, MA). The secondary antibody was goat anti–mouse Alexa Fluor 488 (Invitrogen). TO-PRO-3 iodide (642/661) (Invitrogen) was added to the staining to monitor nuclear structure. Immunofluorescence was observed with the use of the Nikon Eclipse 800 microscopy with the Bio-Rad Radiance 2000 confocal fluorescence microscope system (Bio-Rad Laboratories, Hercules, CA).

Reagents

To explore the possible pathways of HCV replication on ROS and TGF-β1 up-regulation, Huh7.5.1 cells or JFH1 cells were incubated with several pathway inhibitors, including diphenyliodonium (DPI; ROS inhibitor), SB 203580 (SB; p38 MAPK inhibitor), SP600125 (SP; JNK inhibitor), U0126 (ERK1/2 inhibitor), LY 294002 (LY; phosphoinositol-3 kinase [PI3K] inhibitor), or AQ, 6-aminohexanoate (4-phenoxyphenylethylamino) quinazoline (NFκB activation inhibitor). The inhibitors were purchased from EMD Chemicals, Inc, Gibbstown, NJ. The inhibitor stock solution was dissolved in 1% dimethyl sulfoxide (DMSO). The cells were incubated with different inhibitors at a final concentration of 20 μmol/L for 14 hours; 1% DMSO was used as a negative control.

Real-Time Polymerase Chain Reaction

Total cellular RNA was harvested with the use of the QIA shredder kit and RNeasy kit (QIAGEN, Valencia, CA) according to the manufacturer’s protocol. Total cDNA was synthesized by reverse transcription with the GeneAmp RNA PCR (polymerase chain reaction) Kit (Applied Biosystems, Branchburg, NJ). TGF-β1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA levels were quantified by real-time PCR. Human TGF-β1 (GeneBank no. NM_000660) was measured with the following primers: sense primer, GGC CAG ATC CTG TCC AAG C; antisense primer, GTG GGT TTC CAC CAT TAG CAC. Human GAPDH (GeneBank no. BC026907; GAPDH sense primer, ACA GTG CAT TTC ACC ACC TTC TGG; GAPDH antisense primer, GCC TGC TTC ACC ACC TTC TTG) was used as a control for basal RNA levels. TGF-β1 and GAPDH levels were quantified by real-time PCR with the use of the Bio-Rad IQ5 (Bio-Rad Laboratories) and Finnzymes SYBR green I dye (New England Biolabs, Ipswich, MA) for detection as previously described.19

TGF-β1 Enzyme-Linked Immunoabsorbent Assay

TGF-β1 cytokine levels in supernatants were measured with the Quantikine Human TGF-β1 enzyme-linked immunoabsorbent assay kit (R&D Systems, Minneapolis, MN).

Protein Sample Preparation

At the time of harvest, cells were washed with PBS, and whole cell protein samples were extracted with radiimmunoprecipitation assay buffer (0.5% Nonidet p-40, 10 mmol/L Tris, pH 7.4, 150 mmol/L NaCl, 1% sodium dodecyl sulfate) with a protease inhibitor cocktail (Sigma Life Science and Biochemicals, St Louis, MO). Whole protein lysates were sonicated, boiled at 95°C for 5 minutes, and chilled on ice for 5 minutes before Western blot assay.
**Western Blot**

Western blot was performed as previously reported.\(^1,2\) Protein (20 µg/well) was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis with precast NuPAGE Novex 4%–12% Bis-Tris gradient gels (Invitrogen, Carlsbad, CA) and transferred to polyvinylidene fluoride membranes. The primary antibodies used for the Western blots included phosphorylated and unphosphorylated p38 MAPK, JNK, ERK1/2, PI3K, and NFκB (p65) (Cell Signaling Technology, Inc, Danvers, MA); mouse anti-HCV NS5A (ViroGen Co, Watertown, MA); mouse anti-HCV core (Affinity BioReagents Inc, Golden, CO), and mouse antiactin (Sigma Life Science and Biochemicals). The secondary antibodies included horseradish peroxidase–conjugated electrochemiluminescence (ECL) donkey anti–rabbit immunoglobulin G, or horseradish peroxidase–conjugated ECL sheep anti–mouse immunoglobulin G (Amersham Biosciences, Piscataway, NJ). The ECL Western Blotting Detection Kit (Amersham Biosciences) was used to detect chemiluminescent signals.

**Luciferase Reporter Assay**

To assess the effect of JFH1 HCV infection on NFκB signaling, Huh7.5.1 cells or JFH1-infected Huh7.5.1 cells were cotransfected with an NFκB promoter construct expressing firefly (pNFκB-Luc; Stratagene, La Jolla, CA) and construct pRL-TK expressing Renilla luciferase. FuGene HD Transfection Reagent (Roche Diagnostics, Indianapolis, IN) was used for plasmid transfection. Dual-luciferase assay (Promega, Madison, WI) was assessed for luciferase activity. Relative luciferase activity (RLA) was normalized by dividing the firefly luciferase value by the Renilla luciferase value.

**Short Interfering RNA and Transfection**

To further determine the specific molecular pathways of HCV replication on ROS production and TGF-β1 expression, we performed RNAi to knock down several pathway genes expression. The short interfering RNAs (siRNAs) were transfected into cells with the HiPer-Fect Transfection Reagent (QIAGEN). The siRNAs used for gene knock-down were as follows: SignalSilence p38 MAPK siRNA, SignalSilence p44/42 ERK siRNA, SignalSilence NFκB p65 siRNA (Cell Signaling Technology, Inc), On-Target SMARTpool JNK1 siRNA, On-Target SMARTpool PI3K siRNA (Dharmacon, Inc, Lafayette, CO). QIAGEN AllStars Neg (negative) siRNA (QIAGEN) was used as a negative control for siRNA transfection. The protein expression of each knockdown gene was confirmed by Western blot.

**Statistics**

Data analysis was carried out with the use of a 2-tailed Student’s t test with pooled variance. Data are expressed as mean ± SD of at least 4 sample replicates, unless stated otherwise. In the figures, * denotes \( P < .05 \), **\( P < .01 \), and ***\( P < .001 \).

![Figure 1](https://example.com/figure1.png)

**Figure 1.** HCV increases TGF-β1 mRNA and ROS production in JFH1-infected Huh7.5.1 cells. (A) JFH1 HCV induces ROS production. ROS level was normalized by cell viability to calculate the ROS/cell viability arbitrary unit \( n = 4; \ P = .001 \). (B) JFH1 increased ROS fluorescence. ROS fluorescent images in Huh7.5.1 and JFH1 live cells. (C) JFH1 HCV increases TGF-β1 expression. TGF-β1 level was normalized to GAPDH level to calculate the TGF-β1/GAPDH arbitrary unit \( n = 4; \ P = .007 \). (D) Western blot for HCV NSSA and HCV core. HCV NSSA, HCV core, and actin proteins levels were detected by Western blots.
Results

**HCV Increases TGF-β1 mRNA and ROS Production in JFH1 Cells**

We first examined whether HCV infection has an effect on ROS production in JFH1 cells. We found a >2-fold increase of ROS production in JFH1 cells compared with Huh7.5.1 cells (Figure 1A; $P = .001$). To visualize ROS activity in Huh7.5.1 cells and JFH1 cells, fluorescent images of the cells were obtained. We confirmed that live cells infected with JFH1 HCV contained higher levels of ROS than uninfected Huh7.5.1 cells (Figure 1B). We found that HCV infection enhances TGF-β1 expression in a previous report. In this study, we confirmed again that HCV increases TGF-β1 expression by >3-fold in JFH1 cells compared with Huh7.5.1 cells (Figure 1C; $P = .007$). Western blot for HCV NS5A and HCV core confirmed expression of viral proteins in JFH1 cells (Figure 1D). With the use of fluorescent microscopy, we found that there ≥95% of the cells were infected with JFH1 (Supplementary Figure 1).

**HCV Up-regulation of TGF-β1 Expression Is ROS Dependent**

To determine whether HCV induction of TGF-β1 expression is linked to ROSs, we used DPI, a blocker of ROS formation. We found that DPI completely blocked not only HCV-induced ROS production but also abrogated TGF-β1 enhancement (Figure 2A and B).

**HCV-Induced Oxidative Stress Regulates TGF-β1 Expression Through p38 MAPK, JNK, and ERK**

We then asked how ROSs regulates TGF-β1 expression. Because ROSs are possible upstream signaling molecules to the cellular kinases p38 MAPK, JNK, and ERK, we examined the interactions of ROS generation with these proteins in JFH1 cells. We monitored ROS production and TGF-β1 expression in Huh7.5.1 cells or JFH1 cells treated with several different pathway inhibitors. The p38 MAPK inhibitor SB, JNK inhibitor SP, or ERK inhibitor U0126 had no effect on HCV-induced ROS production (Figure 2A), but they partially blocked

---

**Figure 2.** The ROS inhibitor DPI blocks HCV up-regulation of TGF-β1. The inhibitors used included DPI, SB, SP, U0126, or LY; 1% DMSO was used as a negative control. (A) DPI blocked JFH1 HCV-mediated ROS generation. ROS level was normalized by cell viability to calculate the ROS/cell viability arbitrary unit. DPI completely blocked the HCV-induced ROS production compared with JFH1 in DMSO ($P < .001$; n = 4). (B) DPI inhibited JFH1 HCV-mediated TGF-β1 expression. TGF-β1 level was normalized to GAPDH level to calculate the TGF-β1/GAPDH arbitrary unit. DPI completely blocked the HCV-stimulated TGF-β1 production ($P = .002$), SB, SP, or U0126 partially reduced TGF-β1 production by 29.5% ($P = .08$), 32.2% ($P = .07$), and 27.5% ($P = .1$), respectively, compared with JFH1 in DMSO (n = 4). In contrast, LY had no effect on TGF-β1 expression. (C) The ROS inhibitor DPI blocked phosphorylation of p38 MAPK, JNK, ERK. JFH1 HCV activated the phosphorylation of p38 MAPK, p42 ERK, and JNK (lane 2). ROS inhibitor DPI blocks phosphorylation of p38 MAPK, JNK, ERK to levels comparable to those seen with their specific inhibitors (lane 3). Antibody to PI3K was directed against unphosphorylated protein. We found that HCV does not activate PI3K phosphorylation (data not shown). Lane 1, Huh7.5.1 + DMSO; lane 2, JFH1 + DMSO; lane 3, JFH1 + DPI; lane 4, JFH1 + SB; lane 5, JFH1 + SP; lane 6, JFH1 + U0126; lane 7, JFH1 + LY.
TGF-β1 expression in JFH1 cells (Figure 2B). In contrast, the PI3K inhibitor LY had no effect on HCV-mediated enhancement of TGF-β1 or ROS production (Figure 2A and B). Western blotting showed that JFH1 induces the phosphorylation of p38 MAPK, JNK1/2, and p44/42 ERK (Figure 2C). Furthermore, the ROS inhibitor DPI blocked phosphorylation of p38 MAPK, JNK, and ERK to levels comparable to those seen with their specific inhibitors (Figure 2C). These data therefore suggest that p38 MAPK, JNK, and ERK lie downstream of ROS. These results also indicate that HCV stimulates ROS generation, which in turn induces phosphorylation of p38 MAPK, JNK1/2, and p44/42 ERK. These intermediates ultimately contribute to the up regulation of TGF-β1 expression.

HCV-Induced TGFβ1 Expression Is Partially Blocked by siRNA of p38 MAPK, JNK, or ERK

To further test the specific effects of HCV replication on ROS production and TGF-β1 expression pathways, we performed siRNA-mediated knockdowns of p38 MAPK, JNK, ERK, or PI3K. We then assessed ROS production and TGF-β1 expression in these cells. We found that siRNA knockdown of p38 MAPK, JNK, ERK, or PI3K had no effect on ROS production in JFH1 cells (Figure 3A). However, we found that TGF-β1 mRNA expression was partially reduced by p38 MAPK, JNK, or ERK siRNA knockdown (Figure 3B). In contrast, PI3K siRNA had no effect on TGF-β1 expression (Figure 3B). Data from enzyme-linked immunoabsorbent assay showed that the...
knockdown of p38 MAPK, JNK, or ERK significantly reduced TGF-β1 cytokine protein levels to 1105 ± 88 pg/mL, 1102 ± 95 pg/mL, and 1073 ± 105 pg/mL, respectively, compared with Neg siRNA in JFH1 cells (1571 ± 111 pg/mL; Figure 3C). We confirmed successful knockdown of p38 MAPK, JNK, ERK, or PI3K via Western blotting (Figure 3D). These data further show that HCV activated ROS production and subsequently increased TGF-β1 mRNA and protein expression through the p38 MAPK, JNK, and ERK pathways.

**Combination of siRNA to p38MAPK and ERK Cooperatively Reduces TGF-β1 Production**

To assess the effect of both p38 MAPK and ERK on TGF-β1 expression in JFH1 cells, we performed siRNA to knock down both p38 MAPK and ERK. We found that the combination of siRNAs to p38 MAPK and ERK additively reduced TGF-β1 mRNA expression (Figure 4A). TGF-β1 levels in supernatants were significantly lower in the combination siRNAs to p38 MAPK and ERK (596 ± 73 pg/mL) compared with Neg siRNA in JFH1 cells (1571 ± 111 pg/mL; Figure 4B). Western blot confirmed the knockdown of p38 MAPK and ERK proteins (Figure 4C). We also found a cooperative reduction of NFκB phosphorylation with the combination of siRNA to p38 MAPK and ERK (Figure 4C).

**Inhibition of ROSs Blocks HCV-Activated NF-κB Signaling**

To assess the possibility that HCV-mediated up-regulation of TGF-β1 occurs through the NF-κB pathway, we monitored NF-κB promoter-driven luciferase activity in uninfected Huh7.5.1 or JFH1-infected cells treated with different pathway inhibitors. We found that JFH1 activated NFκB signaling (Figure 5A). The ROS inhibitor DPI completely abrogated NFκB signaling to a level comparable to that observed with the NFκB inhibitor AQ. We found that SB, SP, and U0126 also reduced NFκB signaling by 82.9%, 76.7%, and 52.1%, respectively. In contrast, LY did not affect NFκB signaling (Figure 5A). These data indicate that ROS-induced NFκB signaling proceeds through p38 MAPK, JNK, and ERK. Western blotting showed that JFH1 activated NFκB phosphorylation and that DPI inhibited JFH1-driven NFκB phosphorylation to a comparable degree to the NFκB inhibitor AQ. In parallel with the functional expression data, SB, SP, or U0126 also partially reduced JFH1-induced NF-κB phosphorylation. In contrast, LY had no effect on NF-κB phosphorylation (Figure 5B). It is possible that
NFkB-luciferase reporter induction is more sensitive to DPI than is formation of phospho-NFkB, which correlates more strongly with TGF-β1 expression. In either event, the observation of a strong correlation between NFkB induction and TGF-β1 supports NFkB regulation of TGF-β1.

**HCV-Induced TGF-β1 Expression Is Abrogated by NFkB siRNA**

To show that NFkB participates in HCV-mediated enhancement of TGF-β1 expression, we performed siRNA-mediated knockdown of NFkB. We found that JFH1 HCV-mediated enhancement of TGF-β1 expression was blocked by NFkB-specific siRNA but not by a negative control siRNA (Figure 6A). We also confirmed that NFkB siRNA significantly inhibited JFH1 HCV-activated TGF-β1 cytokine protein production (Figure 6B). These data confirm that HCV-mediated enhancement of TGF-β1 depended on NFkB activation. However, we found that HCV-mediated ROS production was not inhibited by NFkB siRNA (Figure 6C), indicating that ROS production was independent of NFκB activation. We also found that JFH1-activated NFkB signaling was inhibited by NFkB siRNA but not by a negative control siRNA (Figure 6D). Western blotting confirmed that NFkB protein expression was knocked down by NFkB siRNA but not by a negative control siRNA (Figure 6E).

**Discussion**

HCV infection can lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma through multiple mechanisms. HCV-induced TGF-β1 production appears to play a key role in the development of hepatic fibrosis. TGF-β1 is the most potent known profibrogenic factor. However, the molecular mechanism by which HCV induces TGF-β1 is not well characterized. It has been hypothesized that oxidative stress could contribute to the development of liver fibrosis by inducing the overproduction of TGF-β1 and angiotensin II.21,22

Using an infectious cell culture model of HCV, we demonstrate for the first time that HCV induces TGF-β1 through the generation of ROSs. Our data further indicate that ROSs induce TGF-β1 through the activation of p38 MAPK, JNK, and ERK pathways, which in turn stimulate NFkB phosphorylation. The activated NFkB subsequently induces TGF-β1 expression. Our data provide new insights into a direct mechanism of liver fibrogenesis by HCV infection through the induction of ROSs, NFkB, and TGF-β1.

It has been previously shown that HCV can induce ROS production in HCV core, NS3, and NS5 protein expression models and in HCV replicon models.4, 6–8 HCV core expression has also been shown to induce the activation of JNK, p38 MAPK, JNK, and ERK pathways in the regulation of TGF-β2 and vascular endothelial growth factor proteins.23 HCV infection has also been linked to endoplasmic reticulum stress, which is associated with ROS production in chronically infected patients.15 ROSs can induce the proliferation of HSCs and release of TGF-β1. ROSs have also been shown to mediate TGF-β1–induced cellular responses in renal cells.11 This probably plays an important role in the development of liver fibrosis associated with the HCV infection.13 ROS-mediated activation of the p38 MAPK, JNK, ERK, and NFkB pathways have been reported in multiple in vitro and in vivo models. It has been shown that ROSs are required to activate p38/Smad3 signaling and the release of active and latent TGF-β1 in stromal cells.24 Elevation of ROSs has also been reported to induce phosphorylation of p38 MAPK in hematopoietic stem cells.25 ROSs have also been shown to increase TGF-β1 expression in rat HSCs through...
activation of the MAPK pathway, including p38 MAPK, JNK, ERK, and NFκB.24,27 Our study, unlike previous work, is the first systematic investigation of the mechanisms of HCV-induced ROS generation and TGF-β1 production with the use of the JFH1 infectious HCV model.16,17 The finding that HCV directly induces profibrogenic cytokine release from hepatocytes in a ROS-dependent, p38 MAPK, JNK, and ERK-dependent manner is a novel one.

NFκB is one of the main signal-transduction molecules activated in response to oxidant stress. Activation of NFκB and its target genes is crucial for induction of immune responses and cell proliferation.28,29 It has been reported that the NFκB pathway may regulate TGF-β1 production during the resolution of inflammation in vivo; inhibition of NFκB reduced TGF-β1 expression in leukocytes.30 Our study now shows that ROS-induced NFκB regulates TGF-β1 expression in the HCV-infected hepatocyte.

It should be noted that TGF-β1 is highly pleiotropic and could also produce beneficial effects on suppression of proliferative activity,31,32 so that not all effects of viral infection may be maladaptive. Nonetheless, the central role of TGF-β1 in fibrogenesis makes its predominant effect profibrogenic. Although it has been reported that viral protein expression can inhibit TGF-β reporter gene activity through a direct interaction between HCV core and Smad3,31 our data strongly support that in the context of whole viral infection there is strong induction of TGF-β1.

Our study provides new evidence, using an infectious tissue culture model, that HCV directly increases ROS and TGF-β1 expressions. We propose a unique model in
which HCV induces ROS generation, which in turn activates the phosphorylation of p38 MAPK, JNK, and ERK. The phosphorylated p38 MAPK, JNK, and p42/44 ERK subsequently induces the phosphorylation of NFkB. The activated NFkB translocates to the nucleus, up-regulating cytokine genes, including TGF-$\beta$1 (Figure 7). We conclude that the HCV-mediated TGF-$\beta$1 enhancement occurs through a ROS-induced and p38 MAPK, JNK, ERK1/2, NFkB–dependent pathway. These results support the hypothesis that HCV enhances hepatic fibrosis progression through the generation of ROSs and induction of TGF-$\beta$1. With the demonstration of a direct link between viral infection, generation of oxidative stress, and profibrogenic cytokine release, it would appear that strategies to limit the viral induction of oxidative stress are warranted to inhibit hepatic fibrosis.

Supplementary Material

Note: To access the supplementary material accompanying this article, visit the online version of Gastroenterology at www.gastrojournal.org, and at doi: 10.1053/j.gastro.2010.03.008.

References


Supplementary Figure 1. Fluorescent images of hepatitis C virus (HCV) JFH1-infected cells. Cell nucleus morphology (blue). HCV core in cytoplasm (green). Uninfected Huh7.5.1 cells (top panel). JFH1-infected Huh7.5.1 cells (day 6) (bottom panel).